Longitude Capital is a venture growth fund that focuses on mid- to commercial-stage biotech and medtech companies with clinically de-risked assets, systematically pursuing spin-outs, recapitalizations, PIPEs, and other structured transactions across both private and public companies rather than relying solely on traditional VC rounds. The firm's founding partners have invested together since 2002 and brought in Matthew Young, former COO/CFO of GRAIL, as a co-leading investment partner in 2022, while operating the Longitude Research Network to pipeline frontier academic research directly into deal-sourcing.